自发性系统性红斑狼疮和类风湿关节炎中的乙酰化酶表型
Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.
作者信息
Lawson D H, Henry D A, Lowe J, Reavey P, Rennie J A, Solomon A
出版信息
Ann Rheum Dis. 1979 Apr;38(2):171-3. doi: 10.1136/ard.38.2.171.
Abstract
Acetylator phenotype was determined in 22 patients with spontaneous systemic lupus erythematosus and the proportion of 'slow' acetylators compared with that obtained in a group of patients with rheumatoid arthritis and a group of healthy controls. 73% of the SLE group were designated 'slow' compared with 72% of the rheumatoid group and 64% of the control group. These differences were not significant.
摘要
对22例自发性系统性红斑狼疮患者进行了乙酰化酶表型测定，并将“慢”乙酰化酶的比例与一组类风湿性关节炎患者和一组健康对照者进行了比较。系统性红斑狼疮组中73%被认定为“慢”乙酰化酶，相比之下，类风湿组为72%，对照组为64%。这些差异并不显著。
相似文献
1
Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.自发性系统性红斑狼疮和类风湿关节炎中的乙酰化酶表型
Ann Rheum Dis. 1979 Apr;38(2):171-3. doi: 10.1136/ard.38.2.171.
2
Drug acetylation and expression of lupus erythematosus.药物乙酰化与红斑狼疮的表达
Eur J Clin Pharmacol. 1985;28(4):387-90. doi: 10.1007/BF00544355.
3
Acetylator phenotype in systemic lupus erythematosus.系统性红斑狼疮中的乙酰化酶表型
Arthritis Rheum. 1977 Apr;20(3):815-8. doi: 10.1002/art.1780200309.
4
Polymorphic acetylator phenotype and systemic lupus erythematosus.
Acta Med Scand. 1981;210(3):193-6. doi: 10.1111/j.0954-6820.1981.tb09799.x.
5
Acetylator polymorphism in rheumatoid arthritis.类风湿关节炎中的乙酰化酶多态性
Eur J Clin Pharmacol. 1993;45(3):279-81. doi: 10.1007/BF00315397.
6
Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.日本系统性红斑狼疮患者的乙酰化表型及异烟肼的代谢情况
Arthritis Rheum. 1981 Oct;24(10):1245-54. doi: 10.1002/art.1780241004.
7
Normal distribution of acetylation phenotypes in systemic lupus erythematosus.系统性红斑狼疮中乙酰化表型的正态分布。
Arthritis Rheum. 1978 Mar;21(2):192-5. doi: 10.1002/art.1780210203.
8
Acetylator phenotype in idiopathic systemic lupus erythematosus.特发性系统性红斑狼疮中的乙酰化酶表型
Arthritis Rheum. 1980 May;23(5):569-73. doi: 10.1002/art.1780230508.
9
Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus.乙酰化酶表型与系统性红斑狼疮之间缺乏关联的进一步证据。
Arthritis Rheum. 1986 Apr;29(4):508-14. doi: 10.1002/art.1780290408.
10
Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.药物乙酰化表型与自发性系统性红斑狼疮的发生无关。
Arthritis Rheum. 1979 Jul;22(7):777-80. doi: 10.1002/art.1780220714.
引用本文的文献
1
N-acetyltransferase-2 genotypes among patients with rheumatoid arthritis attending Jordan University Hospital.约旦大学医院类风湿关节炎患者的N-乙酰转移酶-2基因型
Genet Test Mol Biomarkers. 2012 Sep;16(9):1007-10. doi: 10.1089/gtmb.2012.0062. Epub 2012 Jun 25.
2
Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.异烟肼代谢、日本特发性系统性红斑狼疮患者与对照受试者的异烟肼表型分析方法比较及乙酰化酶分布
Br J Clin Pharmacol. 1982 Mar;13(3):361-74. doi: 10.1111/j.1365-2125.1982.tb01387.x.
3
Acetylator phenotype and lupus erythematosus.乙酰化酶表型与红斑狼疮
Clin Pharmacokinet. 1981 Mar-Apr;6(2):118-34. doi: 10.2165/00003088-198106020-00003.
4
Survey of the human acetylator polymorphism in spontaneous disorders.自发性疾病中人类乙酰化多态性的调查。
J Med Genet. 1984 Aug;21(4):243-53. doi: 10.1136/jmg.21.4.243.
5
Drug acetylation and expression of lupus erythematosus.药物乙酰化与红斑狼疮的表达
Eur J Clin Pharmacol. 1985;28(4):387-90. doi: 10.1007/BF00544355.
6
Acetylator polymorphism in discoid lupus erythematosus.盘状红斑狼疮中的乙酰化酶多态性
Eur J Clin Pharmacol. 1988;34(3):307-8. doi: 10.1007/BF00540961.
7
Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.影响柳氮磺胺吡啶治疗类风湿关节炎疗效和毒性的因素。综述。
Drugs. 1986;32 Suppl 1:54-7. doi: 10.2165/00003495-198600321-00011.
8
Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.乙酰化表型对柳氮磺胺吡啶治疗类风湿关节炎疗效和毒性的影响。
Ann Rheum Dis. 1985 Dec;44(12):831-7. doi: 10.1136/ard.44.12.831.
9
Genetically determined variability in acetylation and oxidation. Therapeutic implications.乙酰化和氧化的基因决定变异性。治疗意义。
Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003.
本文引用的文献
1
HUMAN ACETYLATION POLYMORPHISM.人类乙酰化多态性
J Lab Clin Med. 1964 Mar;63:394-403.
2
Genetic control of isoniazid metabolism in man.人体中异烟肼代谢的遗传控制。
Br Med J. 1960 Aug 13;2(5197):485-91. doi: 10.1136/bmj.2.5197.485.
3
The polymorphic acetylation of dapsone in man.氨苯砜在人体内的多态性乙酰化作用。
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225-38. doi: 10.1002/cpt1971122part1225.
4
Relation of hydralazine plasma concentration to dosage and hypotensive action.肼屈嗪血浆浓度与剂量及降压作用的关系。
Clin Pharmacol Ther. 1972 May-Jun;13(3):420-5. doi: 10.1002/cpt1972133420.
5
Simplified method for determining acetylator phenotype.确定乙酰化酶表型的简化方法。
Br Med J. 1972 Aug 26;3(5825):506-7. doi: 10.1136/bmj.3.5825.506.
6
The acetylator phenotype of patients with systemic lupus erythematosus.系统性红斑狼疮患者的乙酰化酶表型。
Drug Metab Dispos. 1974 Jan-Feb;2(1):71-3.
7
Spontaneous systemic lupus erythematosus and acelylator phenotype.
Acta Med Scand. 1977;201(3):223-6. doi: 10.1111/j.0954-6820.1977.tb15686.x.
8
Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases.
Acta Med Scand. 1977;201(3):217-22. doi: 10.1111/j.0954-6820.1977.tb15685.x.
9
Drug-induced antinuclear antibodies and lupus syndromes.药物性抗核抗体与狼疮综合征
Drugs. 1976;12(1):69-77. doi: 10.2165/00003495-197612010-00003.
10
Disease and acetylation polymorphism.疾病与乙酰化多态性
Clin Pharmacokinet. 1977 May-Jun;2(3):182-97. doi: 10.2165/00003088-197702030-00003.
Zotero 插件